Salvatore Provenzano
A5046721152- Sarcoma Diagnosis and Treatment
- Tuberous Sclerosis Complex Research
- COVID-19 and healthcare impacts
- Soft tissue tumor case studies
- Vascular Tumors and Angiosarcomas
- Cardiac tumors and thrombi
- Bone Tumor Diagnosis and Treatments
- Oral and Maxillofacial Pathology
- COVID-19 Clinical Research Studies
- Renal cell carcinoma treatment
- Endodontics and Root Canal Treatments
- Lymphoma Diagnosis and Treatment
- Cancer and Skin Lesions
- Long-Term Effects of COVID-19
- Breast Lesions and Carcinomas
- Histiocytic Disorders and Treatments
- Soft tissue tumors and treatment
- SARS-CoV-2 and COVID-19 Research
- Cancer Diagnosis and Treatment
- Breast Cancer Treatment Studies
- Neurofibromatosis and Schwannoma Cases
- Tumors and Oncological Cases
- Neutropenia and Cancer Infections
- Cancer Research and Treatments
- Musculoskeletal synovial abnormalities and treatments
Fondazione IRCCS Istituto Nazionale dei Tumori
2016-2025
University of Padua
2022
Tumori Foundation
2022
Policlinico San Matteo Fondazione
2021
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2021
Istituti di Ricovero e Cura a Carattere Scientifico
2021
University of Palermo
2009-2017
Abstract The SARS-CoV-2 pandemic significantly affected oncology practice across the globe. There is uncertainty as to contribution of patients' demographics and oncologic features severity mortality from COVID-19 little guidance role anticancer anti–COVID-19 therapy in this population. In a multicenter study 890 patients with cancer confirmed COVID-19, we demonstrated worsening gradient breast hematologic malignancies showed that male gender, older age, number comorbidities identify subset...
Epidemiological data for sarcoma in adolescents and young adults (AYAs) across age groups are limited. We aim to: 1) update incidence, survival, changes over time European AYAs; 2) provide an updated comparison of survival AYAs versus children mature adults. calculated crude incidence rates (IR) per 100,000 population year from 2006 to 2013. Using the period approach, we 5-year relative (RS) follow-up 2010-2014. estimated bone (BS) soft tissue (STS) subtypes years 2000-2013. In AYAs, IR was...
Abstract Purpose: Perivascular epitheliod cell tumors (PEComas) are rare mesenchymal neoplasms for which the role of systemic treatments is not established as there no published prospective clinical trials or sufficiently large retrospective case series. The aim this study to clarify activity conventional chemotherapy and biological agents in advanced/metastatic PEComas. Experimental Design: This was an observational, retrospective, international that included patients with PEComa treated...
We explore the pattern of late recurrence (LR) in solitary fibrous tumor (SFT), focusing on histopathologic characteristics, clinical presentation and patients (pts) outcome. Clinical records all pts with confirmed pathologic diagnosis SFT treated at our Institution from 2005 to 2011 were reviewed. analysed data who relapsed ≥10 years after initial diagnosis. A total 14 identified. The primary site origin was pleura (5 pts), pelvis (4 head neck (3 pts) retroperitoneum (2 pts). Primary a...
Abstract Background Alveolar soft part sarcoma (ASPS) is an exceedingly rare and orphan disease, without active drugs approved in the front line. Pazopanib trabectedin are licensed for treatment from second-line, but very little contradictory data available on their activity ASPS. Lacking ongoing and/or planned clinical trials, we conducted a multi-institutional study involving reference sites Europe, U.S., Japan, within World Sarcoma Network, to investigate efficacy of pazopanib...
Fifteen percent of patients with cancer experience symptomatic sequelae, which impair post-COVID-19 outcomes. In this study, we investigated whether a proinflammatory status is associated the development COVID-19 sequelae.
To report on a retrospective study of primary DSRCT aiming at characterizing long-term survivors (LTS).All consecutive patients treated our institution for between 2000 and 2021 were retrospectively identified. Patients received multiagent chemotherapy ± surgery hyperthermic intraperitoneal (HIPEC) whole abdomino-pelvic radiotherapy (WAP-RT) high-dose maintenance (MC). Event-free survival (EFS) overall (OS) estimated by Kaplan-Meier method. alive, without evidence disease ≥36 months from...
We report on the activity of anthracycline-based and high-dose prolonged-infusion ifosfamide chemotherapy in a retrospective series patients affected by advanced myxofibrosarcoma treated at Istituto Nazionale Tumori Milan, Italy, within Italian Rare Cancer Network (RTR).Advanced with anthracycline + as single agent from November 2001 to December 2016 were retrospectively reviewed. All pathological diagnosis centrally reviewed least two expert pathologists. Response was evaluated RECIST,...
Abstract Background Herein, we present the results of phase 2 IMMUNOSARC study (NCT03277924), investigating sunitinib and nivolumab in adult patients with advanced bone sarcomas (BS). Methods Progressing a diagnosis BS were eligible. Treatment was comprised (37.5 mg/day on days 1–14, 25 afterword) plus (3 mg/kg every weeks). Primary end point progression‐free survival rate (PFSR) at 6 months based central radiology review. Secondary points overall (OS), response (ORR) by Response Evaluation...
Cyclooxigenase (COX) is the rate-limiting enzyme for conversion of arachidonic acid (AA) to prostaglandins (PGs). Two isoforms COX have been identified: COX-1 constitutively expressed in many cells and involved cell homeostasis, angiogenesis cell-cell signalling; COX-2 not normal condition however it strongly inflammation. The oral cavity constantly exposed physical chemical trauma that could lead mucosal reactions such as hyperplasia, dysplasia cancer. Early diagnosis most important issue...
IntroductionDesmoid tumour (DT) is a locally aggressive fibroblastic proliferative disease representing the most common extraintestinal manifestation of familial adenomatosis polyposis (FAP). As data on activity chemotherapy in these patients are limited, we examined outcomes treated with low-dose methotrexate (MTX)+vinca alkaloids (vinorelbine or vinblastine).Patients and methodsWe retrospectively reviewed clinical outcome from all confirmed FAP-associated DTs weekly MTX+vinca seven...